Cite
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
MLA
Ezzedine, Khaled, et al. “Efficacy and Safety of Oral Ritlecitinib for the Treatment of Active Nonsegmental Vitiligo: A Randomized Phase 2b Clinical Trial.” Journal of the American Academy of Dermatology, vol. 88, no. 2, Feb. 2023, pp. 395–403. EBSCOhost, https://doi.org/10.1016/j.jaad.2022.11.005.
APA
Ezzedine, K., Peeva, E., Yamaguchi, Y., Cox, L. A., Banerjee, A., Han, G., Hamzavi, I., Ganesan, A. K., Picardo, M., Thaçi, D., Harris, J. E., Bae, J. M., Tsukamoto, K., Sinclair, R., Pandya, A. G., Sloan, A., Yu, D., Gandhi, K., Vincent, M. S., & King, B. (2023). Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal of the American Academy of Dermatology, 88(2), 395–403. https://doi.org/10.1016/j.jaad.2022.11.005
Chicago
Ezzedine, Khaled, Elena Peeva, Yuji Yamaguchi, Lori Ann Cox, Anindita Banerjee, George Han, Iltefat Hamzavi, et al. 2023. “Efficacy and Safety of Oral Ritlecitinib for the Treatment of Active Nonsegmental Vitiligo: A Randomized Phase 2b Clinical Trial.” Journal of the American Academy of Dermatology 88 (2): 395–403. doi:10.1016/j.jaad.2022.11.005.